CGON (CG Oncology) ROCE %: -28.54% (As of Mar. 2026)


CGON CG Oncology Inc CGON
12 GF Score
Price $71.96
! 6 Warning Signs
View Full Analysis

What is CG Oncology ROCE %?

CG Oncology CGON -1.22% 12 ROCE % is -28.54% as of Mar. 2026. GuruFocus rates CGON with a GF Score™ of 12/100. The stock has 6 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. CG Oncology's annualized ROCE % for the quarter that ended in Mar. 2026 was -28.54%.

CG Oncology  (NAS:CGON) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

CG Oncology ROCE % Related Terms

CG Oncology ROCE % Historical Data

* Premium members only.

The historical data trend for CG Oncology's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CG Oncology ROCE % Chart

CG Oncology Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
-23.50 -38.10 -34.94 -24.97 -25.54

CG Oncology Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -23.46 -28.33 -29.85 -26.68 -28.54
CGON
12GF Score
CG Oncology Inc CGON
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CG Oncology ROCE % Calculation

CG Oncology's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-190.774/( ( (754.797 - 21.368) + (791.592 - 30.836) )/ 2 )
=-190.774/( (733.429+760.756)/ 2 )
=-190.774/747.0925
=-25.54 %

CG Oncology's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-265.556/( ( (791.592 - 30.836) + (1135.262 - 35.216) )/ 2 )
=-265.556/( ( 760.756 + 1100.046 )/ 2 )
=-265.556/930.401
=-28.54 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -28.54% mean?
CG Oncology (CGON) has a ROCE % of -28.54% as of Mar. 2026.
Is CG Oncology's ROCE % too high?
CG Oncology's current ROCE % is -28.54%. Overall, CG Oncology has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does CG Oncology's ROCE % compare to CRSP and XENE?
CG Oncology's ROCE % of -28.54% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. CG Oncology's current ROCE % is -28.54%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CG Oncology stock overvalued right now?
CG Oncology (CGON) has a current ROCE % of -28.54%. The current ROCE % is -28.54%. CG Oncology's overall GF Score™ is 12/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For CG Oncology (CGON), the current ROCE % is -28.54% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CG Oncology Business Description

Address 400 Spectrum Center Drive, Suite 2040, Irvine, CA, USA, 92618
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
12GF Score

Get the complete analysis for CGON

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$71.96
Price